Medicure and Reliance sign cardiovascular drug agreement

INICIO/Noticias Farmacéuticas | Posted 30/10/2020 post-comment0 Post your comment

Medicure Inc announced on 5 October 2020 that it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences Private Limited (RLS) for a cardiovascular drug. Under this agreement, Medicure is responsible for the regulatory approval process for the drug product and is granted the exclusive right to market and sell it in Canada, European Union and the US. The cardiovascular drug is currently unnamed. 

Cardiovascular V18D06

Medicure is a Canadian company that specializes in the development and commercialization of cardiovascular therapies. Two of its current products are tirofiban hydrochloride (Aggrastat), an anticoagulant, and pitavastatin (Zypitamag), a cholesterol-lowering statin.

RLS is a diverse pharmaceuticals company with a focus on biotherapeutics, including biosimilars, regenerative medicine, pharmaceuticals, clinical research services and molecular medicine. RLS has developed a variety of similar biologics and those approved in India include filgrastim in 2008 [1], rituximab in 2015 [2] and bevacizumab in 2016 [3]. However, RLS’s epoetin alfa biosimilar application in Europe was withdrawn in 2011 [4].

Medicure focusses specifically on the US market, while its new Indian collaborator, RLS does not currently have any biosimilar products with FDA approval. The companies are combining their expertise to bring the cardiovascular drug to market in the US and other regions.

Related article
Torrent licenses three ‘similar biologics’ from Reliance

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of filgrastim [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-filgrastim
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of rituximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-rituximab
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-bevacizumab
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Europe [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2020 Oct 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2020 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Prestige-Cytiva partnership and new Korean R & D facility
134 AA010709
INICIO/Noticias Farmacéuticas Posted 09/07/2021
Theramex to market Prolia biosimilar in Europe and Australia
18794124_l
INICIO/Noticias Farmacéuticas Posted 25/06/2021
AbbVie antitrust investigation and Sandoz biosimilar delay
Antitrust V21F04
INICIO/Noticias Farmacéuticas Posted 04/06/2021
Merck partners with Indian drugmakers to increase access to COVID-19 drug
Business Aquisition V13F07
INICIO/Noticias Farmacéuticas Posted 21/05/2021
Most viewed articles
Sobre GaBI
INICIO/Sobre GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
INICIO/Directrices Posted 08/10/2010